Teleflex (NYSE:TFX) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Teleflex (NYSE:TFX) from a market perform rating to an outperform rating in a research note released on Friday, Marketbeat.com reports. They currently have $128.00 price target on the medical technology company’s stock.

TFX has been the subject of a number of other reports. Zacks Research lowered shares of Teleflex from a “hold” rating to a “strong sell” rating in a research note on Monday, March 2nd. Wells Fargo & Company increased their price objective on Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Royal Bank Of Canada increased their price target on shares of Teleflex from $115.00 to $125.00 and gave the stock a “sector perform” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a report on Monday, December 29th. Finally, Wall Street Zen cut shares of Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $139.00.

Teleflex Stock Up 0.0%

Teleflex stock opened at $116.23 on Friday. The firm has a 50 day moving average price of $109.07 and a 200-day moving average price of $116.57. The company has a quick ratio of 2.01, a current ratio of 2.54 and a debt-to-equity ratio of 0.81. Teleflex has a twelve month low of $100.18 and a twelve month high of $141.91. The company has a market capitalization of $5.14 billion, a P/E ratio of -5.66, a P/E/G ratio of 0.72 and a beta of 0.87.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 EPS for the quarter, missing the consensus estimate of $3.73 by ($1.80). Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The firm had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $912.57 million. During the same quarter in the previous year, the company posted $3.89 EPS. Teleflex’s revenue for the quarter was down 28.5% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, equities analysts predict that Teleflex will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.2%. Teleflex’s dividend payout ratio is -6.62%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares during the period. Banque Cantonale Vaudoise increased its stake in shares of Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after buying an additional 113 shares during the period. Hantz Financial Services Inc. raised its holdings in Teleflex by 248.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after buying an additional 199 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Teleflex in the 3rd quarter worth $35,000. Finally, V Square Quantitative Management LLC purchased a new position in shares of Teleflex in the fourth quarter valued at about $37,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Irenic, a ~2% Teleflex shareholder, called for the Board to form a strategic-review sub‑committee with independent directors and to engage potential acquirers — a direct catalyst for takeover interest that can lift valuation expectations. Irenic Comments on Teleflex’s Announcement That It Is Open to Strategic Alternatives
• Positive Sentiment: Raymond James upgraded Teleflex from Market Perform to Outperform with a $128 price target, signaling analyst conviction that there’s upside from either operational improvement or strategic outcomes. Raymond James upgrade coverage
• Neutral Sentiment: Teleflex issued a formal statement reiterating its commitment to value‑maximizing strategies and said management met with Irenic on March 19 to understand their views — indicates engagement but not yet a formal review process. Teleflex Reiterates Commitment to Value‑Maximizing Strategies and Strong Execution
• Neutral Sentiment: Other shareholders and outlets are echoing calls for Teleflex to engage potential buyers, adding public pressure that could push the Board toward a more formal process. Teleflex shareholder urges company engage buyers
• Negative Sentiment: Teleflex pushed back, saying Irenic falsely claimed the company was not open to buyout offers — the public dispute raises governance/uncertainty risk and could deter some bidders or prolong a process. Teleflex says Irenic falsely claimed company was not open for buyout offers
• Negative Sentiment: Fundamentals remain a headwind: Teleflex reported a large recent earnings and revenue miss and guidance that reflects recovery needs — operational weakness could limit strategic options or depress standalone valuation until results improve.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.